Biocon Ltd, in collaboration with its European partner Zentiva, has obtained decentralised procedure approval in the European Union for their complex formulation, Liraglutide, which is used to manage diabetes and support weight management.
The approval covers generic versions of Victoza, indicated for treating Type-2 Diabetes, and Saxenda, used for weight management, Biocon Ltd stated in a regulatory filing.
Victoza and Saxenda are trademarks owned by Novo Nordisk.
What began as an offhand remark has rapidly evolved into one of India’s most unexpected digital-political phenomena. The “Cockroach Janta Party” (CJP), a satirical online movement, has captured national attention, reflecting a...
The State Bank of India (SBI) has officially released its notification for Apprentice Recruitment 2026, announcing a total of 7,150 vacancies across various states in the country. The application process is...
Prime Minister Narendra Modi, during his visit to Oslo, firmly rejected international concerns over press freedom and human rights in India, describing critical reports by certain non-governmental organizations as “misplaced” and lacking...
Amid rising geopolitical tensions in the Middle East, the Reserve Bank of India (RBI) has indicated that prolonged instability in the region could lead to an increase in fuel prices in India....
Industry Insights Magazine delivers expert analysis, trends, and startup stories across sectors like Finance, Healthcare, Manufacturing, and Real Estate. With curated interviews, case studies, and reports, we empower professionals and entrepreneurs with actionable insights, helping them navigate change, discover opportunities, and lead confidently in today’s dynamic business landscape.
Discussion about this post